Pyxis Oncology is trading at $1.76, up 5.06%, with no new company-specific announcement identified to explain the gain.
- The latest investor-relations release is dated October 2.
- The move is consistent with supplied biotech-sector strength, but the sector rally does not establish a direct cause.
- A Wells Fargo Buy-rating reiteration was reported October 16, but is not a new October 19 catalyst.